A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors

Trial Profile

A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Cancer; Carcinoma; Dermatofibrosarcoma; Ewing's sarcoma; Malignant melanoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Jun 2018 Results of phase 1 (n=64) published in the European Journal of Cancer.
    • 13 Mar 2018 This trial has been completed in Spain.
    • 28 Nov 2017 Planned End Date changed from 10 Feb 2020 to 24 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top